Liza Laws speaks with Nikesh Shah, VP, global head of drug safety and pharmacovigilance (PV), and Dr Siva Kumar Buddha, director of pharmacovigilance and head of signal and risk management at Indegene.
Offering 13 topic tracks to choose from, the DIA Global Annual Meeting (scheduled June 19-23) lets attendees chose the path that fits their unique interests.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
An expert from the health tech company explains how AI, natural language processing, and other tools can improve pharmaceutical product safety reporting.
A leader from the pharmacovigilance solutions firm discusses the ins and outs managing safety documentation and offers advice on how to deal with them.
A leader from IQVIA suggests what to look for when seeking ways to automate drug safety processes, while maintaining security and customer satisfaction.
The CRO is offering an expanded range of post-authorization solutions designed to help developers with treatments and vaccines in their product pipeline
A leader from the supply-chain specialist explains vulnerabilities and challenges unique to pharma, and how professionals can safeguard and streamline.
A leader from the anti-counterfeit solutions firm says that while packaging-level efforts may have an effect, on-dose technology is worth a closer look.
The company’s Forensic Chemistry Group comprises a collection of technical professionals using their respective talents to detect and thwart counterfeiting.
The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
While the prevalence of chronic diseases boosts the demand for self-administered treatments, ease of use is becoming more important in device manufacturing, says product specialist.
Charles River is set to acquire Citoxlab for €448m ($510m) in cash, a deal which would bolster the CRO’s safety assessment portfolio to support its long-term organic growth aspirations, says CEO.
Driven by a more than 20% increase in adverse event volumes, Iqvia has developed a SaaS safety platform designed to reduce the cost and complexity of pharmacovigilance activities – and help companies add value back into their business, says VP.
Merck’s agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclica’s AI protein screening platform.
Syneos Health has acquired the UK-based advisory firm Kinapse in a deal that will double its consulting footprint in Europe and further strengthen its commercial offerings – one company's fastest-growing lines of business, says CEO.
